EndoQuest Partners with NVIDIA to Accelerate AI-Powered Endoluminal Surgical Robot

EndoQuest will incorporate NVIDIA’s accelerated-computing hardware and software stack, including Holoscan, CUDA and AI Enterprise across its visualisation subsystem, robotic control module and secure cloud services.

US-based Global medtech company EndoQuest Robotics Inc., known for its invasive endoluminal surgical robots, has announced that it will integrate NVIDIA’s IGX Thor platform, marking a major step toward commercializing the world’s first robot specifically designed for scarless endoluminal surgery.

Under the agreement, EndoQuest will incorporate NVIDIA’s accelerated-computing hardware and software stack, including Holoscan, CUDA and AI Enterprise across its visualisation subsystem, robotic control module and secure cloud services.

EndoQuest’s CEO Eduardo Fonseca explained: “By powering our visualisation, control and secure cloud services with Nvidia’s industry-leading technology, we aim to streamline our system architecture for performance, reliability and clinical scalability.

“This unified architecture is critical to advancing our technology for endoluminal robotic surgery and reaching commercialisation.”

In addition, NVIDIA’s technology will enable low-latency sensor processing, advanced 3D visualisation, and precise, time-synchronised robotic motion control, while also supporting secure cloud connectivity. According to EndoQuest, these capabilities will power fleet management, data services and AI deployment across its robotic platforms, with outcomes from this collaboration expected to inform future product design and commercial strategy.

The ELS System is designed for minimally invasive procedures performed through natural body orifices, eliminating external incisions. Early pre-clinical data demonstrate that robot-assisted endoscopic submucosal dissection (ESD) using the system achieved higher complete en bloc resection rates, shorter procedure times, and fewer muscle injuries or perforations compared to conventional ESD for colonic lesions.

Currently, the platform is being evaluated in the PARADIGM clinical trial for lower GI procedures performed by colorectal surgeons and gastroenterologists.

Stay tuned for more such updates on Digital Health News